Insider Selling: Alphatec (NASDAQ:ATEC) CEO Sells 100,000 Shares of Stock

Alphatec Holdings, Inc. (NASDAQ:ATEC) CEO Patrick Miles sold 100,000 shares of the business’s stock in a transaction dated Wednesday, October 1st. The stock was sold at an average price of $13.96, for a total transaction of $1,396,000.00. Following the completion of the transaction, the chief executive officer owned 5,464,078 shares of the company’s stock, valued at $76,278,528.88. This represents a 1.80% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Patrick Miles also recently made the following trade(s):

• On Tuesday, September 2nd, Patrick Miles sold 300,000 shares of Alphatec stock. The stock was sold at an average price of $15.73, for a total transaction of $4,719,000.00.

Alphatec Stock Performance

Shares of Alphatec stock opened at $13.96 on Friday. The company has a market capitalization of $2.07 billion, a PE ratio of -12.35 and a beta of 1.05. The company has a debt-to-equity ratio of 23.22, a quick ratio of 1.77 and a current ratio of 2.88. The company has a 50-day simple moving average of $15.04 and a two-hundred day simple moving average of $12.55. Alphatec Holdings, Inc. has a one year low of $4.88 and a one year high of $16.70.

Alphatec (NASDAQ:ATEC) last announced its earnings results on Thursday, July 31st. The medical technology company reported $0.02 EPS for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.08. The firm had revenue of $185.54 million during the quarter, compared to the consensus estimate of $178.85 million. The business’s revenue for the quarter was up 27.5% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.29) earnings per share. Alphatec has set its FY 2025 guidance at EPS. Research analysts expect that Alphatec Holdings, Inc. will post -1.08 EPS for the current fiscal year.

Analysts Set New Price Targets

ATEC has been the topic of a number of research analyst reports. Barclays restated an “overweight” rating and set a $22.00 price target (up previously from $21.00) on shares of Alphatec in a research note on Monday, August 4th. Lake Street Capital upgraded Alphatec to a “buy” rating and set a $18.00 price target on the stock in a research note on Monday, June 16th. Canaccord Genuity Group restated a “buy” rating and set a $20.00 price target on shares of Alphatec in a research note on Friday, August 1st. Weiss Ratings restated a “sell (e+)” rating on shares of Alphatec in a research note on Saturday, September 27th. Finally, Wall Street Zen lowered Alphatec from a “buy” rating to a “hold” rating in a research note on Friday, September 26th. Six investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $18.50.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in ATEC. Nuveen LLC acquired a new position in shares of Alphatec during the 1st quarter worth approximately $135,874,000. Granite Investment Partners LLC raised its stake in shares of Alphatec by 320.6% during the 2nd quarter. Granite Investment Partners LLC now owns 1,720,944 shares of the medical technology company’s stock worth $19,102,000 after buying an additional 1,311,748 shares during the period. MetLife Investment Management LLC raised its stake in shares of Alphatec by 1,818.5% during the 1st quarter. MetLife Investment Management LLC now owns 1,213,943 shares of the medical technology company’s stock worth $12,309,000 after buying an additional 1,150,669 shares during the period. Driehaus Capital Management LLC acquired a new position in shares of Alphatec during the 1st quarter worth approximately $10,398,000. Finally, Motley Fool Wealth Management LLC acquired a new position in shares of Alphatec during the 1st quarter worth approximately $9,070,000. 66.35% of the stock is owned by institutional investors and hedge funds.

About Alphatec

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.